GlassScriptPhysician profile
Josue Chery
NPI 1619273786
$11,533.76
in general payments reported to CMS, 2019-2025
14 companies · $7,380 in 2025
The $7,380 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,480 · 2020: $214 · 2021: $66.69 · 2022: $253 · 2023: $1,783 · 2024: $357 · 2025: $7,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,500 · Food and Beverage: $2,646 · Travel and Lodging: $1,374.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,500.00 |
| Food and Beverage | $2,646.07 |
| Travel and Lodging | $1,374.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abiomed | $8,395.94 | 2019-2025 | Impella |
| Atricure, INC. | $1,427.76 | 2019-2024 | |
| Abbott Laboratories | $626.02 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $300.27 | 2023-2024 | Endurant Iis |
| Cvrx, INC. | $260.48 | 2024-2025 | Barostim Neo System |
| Edwards Lifesciences Corporation | $174.42 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $98.90 | 2025 | |
| Alnylam Pharmaceuticals INC. | $74.82 | 2025 | Amvuttra |
| Livanova USA, INC. | $49.80 | 2020-2022 | |
| Getinge USA Sales, LLC | $43.13 | 2021 | |
| Procyrion, INC. | $27.25 | 2025 | Aortix System |
| Baxter Healthcare | $23.72 | 2025 | Floseal |
| Terumo Medical Corporation | $17.30 | 2023 | Relay Plus Thoracic Stent-Graft System |
| Convatec INC. | $13.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Josue Chery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.